Advances in Pharmacologic Treatment of Acute Cerebral Ischemia

Abstract

Abstract: Acute cerebral ischemia is one of the most threating diseases to human health, with extremely complex pathophysiological mechansm. Given that there are almost no ideal therapeutic drugs in clinical, current research has focused on finding new effective pharmacological treatment. Systematically reviewing a number of acute cerebral ischemia literatures at home and abroad, this paper summarized the research situation of various types of anti-cerebral ischemia drugs, with emphasis on the clinical medication in this field.

Key words: Cerebral ischemia, neuroprotection, thrombolysis, vasodilator.

CLC Number:

R964

ZHANG Wen，SONG Jun-ke，DU li-da，ZHANG Xue，DU Guan-hua. Advances in Pharmacologic Treatment of Acute Cerebral Ischemia[J]. Acta Neuropharmacologica, 2014, 4(4): 50-58.

References

[1] Gregory J del Zoppo. Stroke and neurovascular Protection[J].N Engl J Med, 2006, 354(6): 553-555.

[2] Mario Vallon, Chang Jun-lei, Zhang Hai-jing, et al. Developmental and pathological angiogenesis in the central nervous system[J].Cell Mol Life Sci, 2014, 71(18): 3489-3506.

[3] Roger Veronique L, Go Alan S, Lloyd-Jones Donald M, et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American heart association[J]. Circulation, 2012, 125(1): 188-197.

[4] Mark J Alberts, Richard E Latchaw, Andy Jagoda, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition[J]. Stroke, 2011, 42(9): 2651-2665.

[5] Michael A Moskowitz, Eng H Lo, Costantino Iadecola. The science of stroke:mechanisms in search of treatments[J]. Neuron, 2010, 67(2):181-198.

[6] Costantino Iadecola, Josef Anrather. Stroke research at a crossroad: asking the brain for directions[J]. Nat Neurosci, 2011, 14(11):1363-1368.

[7] Liebeskind D S. Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics[J]. Curr Opin Neurol, 2010, 23(1):36-45.

[8] Johansson A, Ahrén B, Nsman B, et al. Cortisol axis abnormalities early after stroke--relationships to cytokines and leptin[J]. J Intern Med, 2000, 247(2):179-187.

[9] Rafael A Posada-Duque, George E Barreto, Gloria P Cardona-Gomez. Protection after stroke: cellular effectors of neurovascular unit integrity[J].Front Cell Neurosci, 2014, 14(8): 231.

[10] Muoio V, Persson P B, Sendeski M M. The neurovascular unit - concept review[J]. Acta Physiol (Oxf), 2014, 210(4): 790-8.

[11] Abe K. Neurological diseases and neurovascular unit (NVU) [J]. Nihon Rinsho, 2014, 72(4): 594-599.

[12] 陆征宇, 董强. 脑缺血后神经血管保护机制和损伤机制研究进展[J].中国脑血管病杂志, 2013, 7(3): 153-159.

[13] Ashfaq Shuaib, Kennedy R Lees, Patrick Lyden, et al. NXY-059 for the treatment of acute ischemic stroke[J]. N Engl J Med, 2007, 357(6):562-571.

[14] Lees Kennedy R, Zivin Justin A, Ashwood Tim, et al. NXY-059 for acute ischemic stroke[J]. N Engl J Med, 2006, 354(6):588-600.

[15] Zhang Junping, Ma Guoxing, Lv Zhi-min, et al. Targeted thrombolysis strategies for neuroprotective effect [J].Neural Regen Res, 2014,9(13):1316-22.

[16] Sherita N Chapman, Prachi Mehndiratta, Michelle C Johansen, et al. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke [J].Vasc Health Risk Manag, 2014, 10: 75-87.

[17] Kennedy R Lees, Erich Bluhmki, Rüdiger von Kummer, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J].Lancet, 2010, 375(9727): 1695-1703.

[18] Gregg C Fonarow, Eric E Smith, Jeffrey L Saver, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes[J]. Circulation,2011,123(7):750-758.

[19] 张茁.缺血性脑卒中急性期抗血小板治疗[J].中国老年心脑血管病杂志,2008,10(12):881-882.

[20] Isabelle L Ruel , Benoît Lamarche, Jean-Francois Mauger, et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency [J]. Arterioscler Thromb Vasc Biol, 2005, 25(12): 2600-2607.

[21] 梁纪文,黄淑芳.阿司匹林在抗血小板治疗中的合理应用[J].中国医刊, 2010, 45(9): 5-7.

[22] Ralph L Sacco, Robert Adams, Greg Albers, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline [J]. Circulation, 2006, 113(10): 409-49.

[23] 张芜, 蒋广元. 依达拉奉对缺血性脑损伤保护作用的研究进展[J].中国医药指南, 2012, 10 (8): 61-63.

[24] Zhou Shan-shan, Yu Gui-chun, Chi Li-jun, et al. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats[J].Neurotoxicology, 2013, 38:136-45.

[25] 杨敏慧, 徐宏伟, 刘秋庭, 等.依达拉奉治疗急性脑梗死的临床应用于观察[J].中国临床研究, 2010, 2 (8): 45-47.

[26] Wang Hai-ping, Li Guang-qian. Protection of edaravone on neurons and its effects on the expression of interleukin-lbeta in juvenile rat hippocampus following status convulsion [J]. Zhongguo Dang Dai Er Ke Za Zhi, 2010, 12(3):205-210.

[27] 梁江红, 魏麓云, 汤晓春, 等.丁苯酞通过增强抗氧化活性保护局灶性脑缺血再灌注大鼠[J].国际脑血管病杂志, 2013, 21 (3): 186-190.

[28] Zhao Wang-hong, Luo Chao, Wang Jue, et al.3-N-butylphthalide improves neuronal morphology after chronic cerebral ischemia[J]. Neural Regen Res, 2014, 9(7):719-726.

[29] 张培蕾, 陆海涛, 朱悦奇, 等.丁苯酞对大鼠局灶性脑缺血再灌注损伤的保护作用[J].介入放射学杂志, 2012, 21 (3): 239-242.

[30] Xiang Jing, Pan Jie, Chen Fu-jun, et al. L-3-n-butylphthalide improves cognitive impairment of APP/PS1 mice by BDNF/TrkB/PI3K/AKT pathway [J]. Int J Clin Exp Med, 2014,7(7):1706-1713.

[31] Li Ling, Zhang Bo, Tao Yun-qian, et al. DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative stress, mitochondrial damage and subsequent cell death after oxygen glucose deprivation in vitro[J].Brain Res, 2009, 1290: 91-101.

[32] Li Jimei, Li Yin, Ogle Molly, et al. DL-3-n-butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway[J].Brain Res, 2010, 1359: 216-226.

[33]张莉,张维库,赵莹,等.丹酚酸A的研究与进展[J].中国中药杂志, 2011, 36(19):2603-2609.

[34]杜冠华, 张均田.丹参水溶性有效成分——丹酚酸研究进展[J].基础医学与临床, 2000, 20(5): 10-14.

[35]李艾林, 李铭源, 王一涛, 等. 丹参药理学活性物质基础研究现状[J].中国药学杂志, 2007, 42(9): 641-646.

[36]王洁,吴俊芳,张均田.总丹酚酸的抗脑缺血研究[J].中国药理学通报, 1999, 15(2):164-6.

[37]任德成, 杜冠华, 张均田.总丹酚酸对脑缺血再灌注损伤的保护作用[J].中国药理学通报, 2002, 18(2): 210-21.

[38] Zhang Heng-ai, Gao Mei, Zhang Li, et al. Salvianolic acid A protects human SH-SY5Y neuroblastoma cells against H?O?-induced injury by increasing stress tolerance ability [J]. Biochem Biophys Res Commun, 2012, 421(3):479-483.

[39] Wang Shou-Bao, Pang Xiao-Bin, Zhao Yan, et al. Protection of salvianolic acid A on rat brain from ischemic damage via soluble epoxide hydrolase inhibition[J]. J Asian Nat Prod Res, 2012, 14(11):1084-1092.

[40]杜冠华, 张均田. 丹酚酸A对小鼠脑缺血再灌注致学习记忆功能障碍的改善作用及作用机制[J].药学学报, 1995, 30(3): 184-190.

[41]张均田.丹酚酸B防治神经退行性疾病的研究进展[J].医药导报, 2007, 26(2): 107-110.

[42]李玉娟,杜冠华.总丹酚酸和银杏提取物对血管平滑肌细胞保护作用的比较[J].中国药学杂志, 2003, 38(11): 844-847.

[43] Kristian Strømgaard, Koji Nakanishi. Chemistry and biology of terpene trilactones from Ginkgo biloba[J]. Angew Chem Int Ed Engl, 2004, 43(13): 1640-1658.

[44]李梅, 刘凯玉, 闫森, 等. 银杏叶提取物、银杏黄酮和银杏内酯B对小鼠脑缺血/再灌注损伤的保护作用[J].徐州医学院学报, 2013, 33(7): 421-424.

[45] Shang Yuan-Hong, Tian Jin-Feng, Hou Min, et al. Progress on the protective effect of compounds from natural medicines on cerebral ischemia [J].Chin J Nat Med, 2013, 11(6):588-595.

[46] Schwarzkopf T M, Hagl S, Eckert G P, et al. Neuroprotection by bilobalide in ischemia: improvement of mitochondrial function[J].Pharmazie, 2013, 68 (7):584-589.

[47] Wu Xiao-mei, Zhou Chen, Du Fang, et al. Ginkgolide B preconditioning on astrocytes promotes neuronal survival in ischemic injury via up-regulating erythropoietin secretion [J].Neurochem Int, 2013, 62 (2): 157-164.

[48] Dorothee Lang, Cornelia Kiewert, Alexander Mdzinarishvili, et al. Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo[J]. Brain Res, 2011,1425:155-163.

[49] Koch E.Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by gink-golides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts[J]. Phytomedicine, 2005, 12(1-2):10-16.

[50]Chen Ruo-Li，Joyce S Balami，Margaret M Esiri，et al．Ischemic stroke in the elderly：an overview of evidence[J]. Nat Rev Neurol, 2010, 6(5):256-265．

[51] Meng Yu-ling, Chopp Michael, Zhang Yan-lu, et al. Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats [J].PLoS One,2014,9(9):e106238.

[52] Kunio Kawamura, Tetsuya Takahashi, Masato Kanazawa, et al. Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats [J]. PLoS One, 2014, 9(6): e98639.

[53] del Zoppo Gregory J. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia[J]. Neuroscience, 2009, 158(3): 972-982.

[54] Vaz Carneiro A, Costa J. Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation [J]. Acta Med Port, 2014, 27(2): 157-159.

[55] Yuen Chun-Man, Sun Cheuk-Kwan, Lin Yu-Chun, et al. Combination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke[J]. J Transl Med, 2011, 9: 141.

[56] Zhao Gang, Zhang Wen, Li Li,et al. Pinocembrin protects the brain against ischemia-reperfusion injury and reverses the autophagy dysfunction in the penumbra area[J]. Molecules, 2014, 19(10): 15786-15798.

[57] Liu Rui, Li Jin-ze, Song Jun-ke,et al. Pinocembrin protects human brain microvascular endothelial cells against fibrillar amyloid-β(1-40) injury by suppressing the MAPK/NF-κB inflammatory pathways [J]. Biomed Res Int, 2014, 2014: 470393.

[58] Liu Rui, Li Jin-ze, Song Jun-ke, et al. Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits[J].Neurobiol Aging, 2014, 35(6): 1275-1285.

[59] Philip V Peplow .Growth factor- and cytokine-stimulated endothelial progenitor cells in post-ischemic cerebral neovascularization[J].Neural Regen Res, 2014, 9(15): 1425-1429.

[60] Brandon P Lucke-Wold, Aric F Logsdon, Ryan C Turner, et al. Aging, the metabolic syndrome, and ischemic stroke: redefining the approach for studying the blood-brain barrier in a complex neurological disease[J].Adv Pharmacol, 2014, 71:411-449.

[61] Song Seung, Park Jong-Tae, Na Joo Young, et al. Early expressions of hypoxia-inducible factor 1alpha and vascular endothelial growth factor increase the neuronal plasticity of activated endogenous neural stem cells after focal cerebral ischemia[J].Neural Regen Res, 2014, 9(9): 912-918.

[62]Koch S, Della-Morte D, Dave K R, et al. Biomarkers for ischemic preconditioning: finding the responders[J].J Cereb Blood Flow Metab, 2014, 34(6): 933-941.
[63]Ren Chuan-cheng, Yan Zhin-min, Wei Ding-tai, et al. Limb remote ischemic postconditioning protects against focal ischemia in rats[J].Brain Res, 2009, 1288: 88-94.

[64]Yuan Ya-jing, Guo Qu-lian,Ye Zhi, et al. Ischemic postconditioning protects brain from ischemia/reperfusion injury by attenuating endoplasmic reticu¬lum stress-induced apoptosis through Pl3K-Akt pathway[J]. Brain Res, 2011, 1367: 85-93.

[65]Abas Faruk, Alkan Tulin, Goren Bulent, et al. Neuroprotective effects of post-conditioning on lipid peroxidation and apoptosis after focal cerebral ischemia/reperfusion injury in rats[J],Turk Neuxosurg, 2010, 20(1):1-8,